Reviews/COPD Pharmacotherapy/Tezepelumab in chronic obstructive pulmonary disease
Emerging Therapies · COPD-EMRG-02 · v2
Borderline: within 4 points of the Doubtful/Refuted boundary, so a re-grade could land either side.
Only one study in this corpus actually tested whether tezepelumab lowers COPD flare-ups: the COURSE trial of 333 patients on triple inhaler therapy [1]. In that trial the drug did not significantly cut the yearly rate of moderate or severe COPD exacerbations (1.75 versus 2.11 for placebo), and the trial's own authors state the primary endpoint was not met [1]. There was a weak numerical lean toward the drug overall, and a larger but still uncertain lean in patients with the highest blood eosinophil counts [1], but the comparison in the lowest-eosinophil group actually favoured placebo [1]. Tezepelumab does reduce exacerbations in asthma [7][8], and it engages COPD-relevant biology [17][18], but those are different diseases or laboratory findings, not COPD flare-up results. The panel treats the claim as stated by one failed trial with only an unconfirmed subgroup hint underneath it.
The single trial measuring the claim's exact outcome, COURSE [1], reported an annualised moderate-or-severe exacerbation rate of 1.75 with tezepelumab versus 2.11 with placebo, rate ratio 0.83 (90% CI 0.64-1.06), with the primary endpoint explicitly not met [1]. Prespecified eosinophil subgroups ranged from a rate ratio of 1.19 (95% CI 0.75-1.90) favouring placebo below 150 cells/μL, to 0.66 (0.42-1.04) at 150 to <300, to 0.54 (0.25-1.15) at ≥300 cells/μL, all crossing no effect [1]. Tezepelumab's exacerbation benefit is established in asthma, with rate ratios of 0.44 in NAVIGATOR [7] and 0.42 over 104 weeks in DESTINATION [8], and COPD tissue work shows TSLP and related signatures tied to disease and eosinophils [17][18]. Narrative and pooled-score reviews [2][3][13] note that anti-TSLP exacerbation data in COPD remained awaited or mixed. No second COPD exacerbation trial appears in the corpus. The contested point: The division is whether the steeper point estimate in the ≥300 eosinophil subgroup (rate ratio 0.54, 95% CI 0.25-1.15) [1] is an early sign of a biomarker-restricted benefit or merely noise from a small, non-significant post-hoc slice. Because the confidence interval spans no effect and the lowest-eosinophil subgroup leaned toward placebo [1], the same data read as either a confirmatory lead or as subgroup overreach.
All 22 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from COPD Pharmacotherapy, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The single pivotal trial [1] explicitly did not meet its primary endpoint (RR 0.83, 90% CI 0.64-1.06, p=0.10 one-sided); the claim asserts as fact an effect the data failed to demonstrate.
The only favourable numbers are non-significant subgroup estimates with CIs spanning no effect and even harm (BEC <150: RR 1.19 favouring placebo); relying on them is post-hoc subgroup overreach.
Where it remains uncertain. A larger but non-significant estimate in the ≥300 eosinophil subgroup (0.54, 0.25-1.15) hints at a possible responder population, while the <150 subgroup favoured placebo (1.19, 0.75-1.90) [1].
Aleatory
With 165 versus 168 patients [1], the overall and subgroup estimates carry wide confidence intervals (e.g. 0.54, 0.25-1.15 at BEC ≥300) that are consistent with both benefit and no effect by chance.
Epistemic
Only one phase 2a COPD exacerbation trial exists in the corpus [1]; whether the direction holds in a larger or confirmatory trial is simply unknown.
Inferential
Asthma exacerbation reductions [7][8] are a different disease and cannot be inferred onto COPD exacerbation outcomes.
The load-bearing papers from a corpus of 22, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Primary endpoint directly on the claim: no significant exacerbation reduction; CI crosses 1.0.
“1·20 versus 2·24 (0·54 [0·25-1·15]) in patients with a baseline BEC of 300 cells per μL or higher.”
Panel auditInternal validity: high · scope of inference: Adults 40-80 with moderate to very severe COPD and >=2 exacerbations in prior year, on triple inhaled therapy.Key limitations: phase 2a, modest size · primary endpoint not met · wide CI crossing 1 · subgroup signals at higher eosinophils remain non-significant
1 of 22 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A single phase 2a RCT that missed its primary exacerbation endpoint cannot carry a positive efficacy claim, leaving only a weak unreplicated subgroup signal.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Confirmatory phase 3 COPD exacerbation trial. The only COPD exacerbation trial in the corpus missed its primary endpoint [1], so the claim has no positive primary evidence to stand on. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A larger, prespecified phase 3 RCT of tezepelumab in exacerbation-prone COPD powered for the annualised moderate-or-severe exacerbation rate.
Open question: Does tezepelumab reduce moderate-to-severe exacerbations in COPD when the trial is powered for that endpoint? Why it is still open: COURSE did not meet its primary exacerbation endpoint and was a phase 2a trial (rate ratio 0.83, 90% CI 0.64-1.06) [1].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19